New hope for rare blood disorder: dupilumab combo trial launches
NCT ID NCT06477653
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding dupilumab to standard treatment can help people with hypereosinophilic syndrome (HES) who still have symptoms despite current biologic therapy. About 30 adults will receive dupilumab injections for up to 48 weeks while continuing their usual medications. Researchers will track symptom changes and side effects to see if the combination offers better control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dupilumab
What this could lead to
If it works, this could offer a new combination treatment to better control symptoms in people with hypereosinophilic syndrome who still have problems despite current therapy.
What could go wrong
This is a small early-phase pilot study with only 30 participants, so results may not apply broadly. Dupilumab can cause side effects like injection reactions or increased eosinophil counts, and it may not improve symptoms for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPEREOSINOPHILIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••